Unlock instant, AI-driven research and patent intelligence for your innovation.

Preparation and application of Trop-2 specific chimeric antigen receptor cell

A chimeric antigen receptor, specific technology, applied to receptor/cell surface antigen/cell surface determinant, for targeting specific cell fusion, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin Equal direction

Inactive Publication Date: 2018-08-24
杭州荣泽生物科技集团有限公司
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

CAR-T has made breakthroughs in hematological tumors through the CD19 target, and some studies have an effective rate of over 90%. However, CAR-T has not yet made a breakthrough in solid tumors, so there is an urgent need for new tumor targets, new CARs Molecular design to advance the field of solid tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and application of Trop-2 specific chimeric antigen receptor cell
  • Preparation and application of Trop-2 specific chimeric antigen receptor cell
  • Preparation and application of Trop-2 specific chimeric antigen receptor cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] This example provides a method for constructing the above-mentioned CAR molecule into the lentiviral vector pCDH

[0046] Construction of Trop2 antibody scFv: Using anti-Trop-2 Fab and Linker (Gly4Ser) 3 as templates, Vκ, V were designed according to the principle of In-FusionPCR H Amplification primers; amplify Vκ, vH fragments and link them with Linker (Gly4Ser) 3 to form Vκ-Linker (Gly4Ser) 3-VH gene fragments (anti-Trop-2 IgG); use restriction endonuclease Nco I Retroviral vector (SFG.CH2CH3-CD28-4-1BB-CD3ζ) containing human CH2CH3 and intracellular signal transduction region CD28, 4-1BB, CD3ζ gene sequence with Xho I double digestion;

[0047] HRS-28bbZ vector construction: The anti-Trop-2 scFv was connected with the linearized retroviral vector by In-Fusion PCR (Table 1) to construct the third-generation Trop-2 CAR retroviral expression plasmid (Trop-2 CAR retroviral expression plasmid (Trop -2 CAR plasmid), carry out enzyme digestion identification and sequenc...

Embodiment 2

[0051] This example is the preparation of Trop-2 CAR-T cells

[0052] Packaging of CAR lentivirus; pCDH Trop-2 CAR-GFP plasmid and lentivirus auxiliary packaging plasmids pMD2.G and pSPAX2 were extracted by QIAGEN endotoxin-free plasmid large extraction kit. 24h before transfection, 2.5×10 7 Spread 293 to T75 cell culture flasks, replace 293T medium with 10ml serum-free medium 1 hour before transfection, use 293fectin TM TransfectionReage transfected 3 plasmids, and 24 hours after the transformation, the medium was replaced with 15ml of complete medium. After 48 hours, the cell supernatant virus liquid was collected. After the virus supernatant was concentrated in a 0.45μm 100kD ultrafiltration tube, it was stored at -80℃ for later use. . The virus titer was detected by qPCR method, and the virus content after the virus supernatant was concentrated 10 times by ultrafiltration was more than 1.5×10 9 copies / ml.

[0053] T cell transduction: CD4+ / CD8+ T cells were separated...

Embodiment 3

[0055] This example is the killing effect of Trop-2 CAR-T cells on ovarian cancer cells in vitro.

[0056] Ovarian cancer cells OVCAR-3, HO8910, SKOV3, A2780, breast cancer cell MCF-7, and melanoma cell A375 were detected by flow cytometry; the expression levels of Trop-2 mRNA in the above cells were detected by RT-PCR (Table 2). The results of flow cytometry and RT-PCR showed that ovarian cancer cells OVCAR-3, H08910 and breast cancer cells MCF-7 highly expressed Trop-2 antigen, ovarian cancer cells SKOV3 lowly expressed Trop-2 antigen, ovarian cancer cells A2780, Melanoma cell A375 does not express Trop-2 antigen, such as Figure 5A and 5B shown.

[0057] Table 2 Amplification primers for Trop2 and GAPDH fragments

[0058]

[0059] Collect the tumor cells HO8910 and A2780 in the logarithmic growth phase, and set 5 density 5×10 5 Cells / ml, 2×10 5 Cells / ml, 1×10 5 Cells / ml, 5×10 4 Cells / ml were added to 96-well cell culture plate at 100 μL / well; after the cells in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses Trop-2 specific chimeric antigen receptor, comprising a signal peptide, an antigen binding region, a hinge region, a transmembrane region, a costimulatory signal transduction region, a CD3 zeta signal transduction region and a T2A short peptide, wherein the signal peptide is CSF2RA signal peptide, the antigen binding region is scFv sequence, the hinge region is CD8 alpha region, the transmembrane region is CD28 transmembrane region, the costimulatory signal transduction region is CD28 and 4-1BB, and the CD3 zeta signal transduction region is CD3 molecular intracellularsignal transduction region; the chimeric antigen receptor is specifically RZ-28bbZ, having a nucleotide coding sequence shown as SEQ ID No. 1. The invention also provides a recombinant expression vector containing the above nucleotide, a host cell with the vector, a construction method of the host cell and application of the vector and host cell in the treatment of tumors in mammals. The Trop-2 specific chimeric antigen receptor helps CAR-T cells efficiently and specifically treat ovarian cancer by T-cell modification.

Description

technical field [0001] The invention relates to the field of immune cell preparation, in particular, the invention relates to a Trop2-specific chimeric antigen receptor and its use. technical background [0002] Ovarian cancer lacks typical clinical manifestations in the early stage, so it is often discovered only when it progresses to an advanced stage. Its five-year survival rate is less than 30%. It is the most common cause of death from female reproductive system tumors and seriously threatens the safety of women's lives. At present, the treatment of ovarian cancer mainly adopts the combined therapy of surgery and chemotherapy, but more than 70% of ovarian cancer patients relapse after the initial treatment, and are prone to tolerance or resistance to chemotherapy. Therefore, it is urgent to explore new ovarian cancer treatments. Clinical treatment methods. [0003] Chimeric antigen receptor T cell immunotherapy (CAR-T) technology is a new method of immunotherapy based ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N5/10A61K35/17A61P35/00
CPCA61K35/17A61P35/00C07K14/7051C07K16/30C07K2317/622C07K2319/02C07K2319/03C07K2319/33C12N15/86C12N2740/15043
Inventor 陈相波雷鸣田朋飞
Owner 杭州荣泽生物科技集团有限公司